New Study Links Ozempic To Vision Loss, Confirms Harvard Research
Another study has been published suggesting that patients taking semaglutide—the active ingredient in Novo Nordisk’s blockbuster drug Ozempic—may face a higher risk of developing a rare eye condition that can lead to blindness. “The glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide has quickly become a key treatment for managing type 2 diabetes and obesity. Recent findings have raised concern …
New Study Links Ozempic To Vision Loss, Confirms Harvard Research Read More »